Reduced Susceptibility to Ischemia-induced Arrhythmias in the Preconditioned Rat Heart is Independent of PI3-kinase/Akt
Overview
Authors
Affiliations
We examined the involvement of phosphatidylinositol 3-kinase (PI3K) and its effector protein kinase B (Akt) in cardioprotective effects of ischemic preconditioning (PC) with particular regards to its role in the protection against ischemia-induced arrhythmias in isolated perfused rat heart. PI3K/Akt inhibitor wortmannin (100 nM) was administered 15 min prior to 30-min regional (left anterior descending coronary artery occlusion) ischemia for the study of ischemic arrhythmias in the hearts perfused at constant coronary flow or prior to 30-min global ischemia followed by 2-h reperfusion for the infarct size (IS) determination (tetrazolium staining) in the hearts perfused at constant pressure. PC procedure (one cycle of ischemia/reperfusion, 5 min each) significantly reduced the total number of ventricular premature complexes (PVC) and severity of arrhythmias (arrhythmia score; AS) over the whole period of left anterior descending coronary artery occlusion in comparison with non-PC controls (PVC 166+/-40; AS 1.6+/-0.2 vs. 550+/-60 and 3.2+/-0.2; respectively; P<0.05). In a setting of global ischemia/reperfusion, PC decreased IS (in % of the left ventricle, LV) by 73 %. Pretreatment with wortmannin modified neither arrhythmogenesis nor IS in the non-PC hearts. Bracketing of PC with wortmannin did not abolish antiarrhythmic protection (PVC 92+/-25; AS 1.7+/-0.2; P<0.05 vs. non-PC hearts). On the other hand, wortmannin increased IS/LV in the PC hearts to 24+/-1.2 % as compared with 9 +/- 0.6 % in the untreated ones (P<0.05). In conclusion, PI3K/Akt inhibition did not affect reduced arrhythmogenesis during ischemia in the PC hearts indicating that in contrast to its positive role in the irreversible myocardial injury, PI3K/Akt activity is not required for protection induced by PC against ischemic arrhythmias in the rat heart.
The Effect of Sumatriptan in Ischemic Conditions in the Rat Heart.
Altunkaynak-Camca H, Tecder-Unal M, Tuncer M Turk J Pharm Sci. 2020; 15(3):328-332.
PMID: 32454677 PMC: 7227824. DOI: 10.4274/tjps.03371.
Dost T Pharmacol Rep. 2020; 72(3):672-679.
PMID: 32048257 DOI: 10.1007/s43440-019-00046-5.
Future Perspective of Diabetic Animal Models.
Pandey S, Dvorakova M Endocr Metab Immune Disord Drug Targets. 2019; 20(1):25-38.
PMID: 31241444 PMC: 7360914. DOI: 10.2174/1871530319666190626143832.
Experimental Diabetes Mellitus in Different Animal Models.
Al-Awar A, Kupai K, Veszelka M, Szucs G, Attieh Z, Murlasits Z J Diabetes Res. 2016; 2016:9051426.
PMID: 27595114 PMC: 4993915. DOI: 10.1155/2016/9051426.
Ravingerova T, Bernatova I, Matejikova J, Ledvenyiova V, Nemcekova M, Pechanova O Exp Clin Cardiol. 2011; 16(3):e23-9.
PMID: 22065943 PMC: 3209549.